Upstream Bio, Inc. (UPB) — SEC Filings
Upstream Bio, Inc. (UPB) — 20 SEC filings. Latest: ARS (Apr 16, 2026). Includes 6 8-K, 3 10-Q, 2 10-K.
View Upstream Bio, Inc. on SEC EDGAR
Overview
Upstream Bio, Inc. (UPB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 16, 2026: Upstream Bio, Inc. filed its Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The report, filed under accession number 0001193125-26-159033, details the company's operations in the pharmaceutical preparations sector. The filing includes the complete
Sentiment Summary
Across 20 filings, the sentiment breakdown is: 2 bearish, 17 neutral, 1 mixed. The dominant filing sentiment for Upstream Bio, Inc. is neutral.
Filing Type Overview
Upstream Bio, Inc. (UPB) has filed 1 ARS, 6 8-K, 1 424B5, 2 10-K, 3 10-Q, 1 DEF 14A, 2 SC 13G, 2 SC 13D, 1 S-1/A, 1 S-1 with the SEC between Sep 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (20)
Risk Profile
Risk Assessment: Of UPB's 16 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-100,000,000 |
| EPS | $-1.84 |
| Debt-to-Equity | 0.0 |
| Cash Position | $150,000,000 |
| Operating Margin | -1000% |
| Total Assets | $200,000,000 |
| Total Debt | $0 |
Key Executives
- Len Blavatnik
- Alejandro Moreno
- Langhorne S. Perrow
- Nicholas
- E. Rand Sutherland
- Michael Paul Gray
Industry Context
Upstream Bio operates in the competitive biotechnology sector, focusing on inflammatory diseases with a lead candidate, verekitug, for severe respiratory disorders. The market for asthma biologics is large and growing, with significant players like Amgen and AstraZeneca already established with TSLP-targeting therapies. The industry trend favors targeted therapies with improved efficacy and convenient dosing, areas where Upstream Bio aims to differentiate verekitug.
Top Tags
pharmaceuticals (3) · Biotechnology (3) · sec-filing (2) · 8-k (2) · pharmaceutical (2) · CRSwNP (2) · COPD (2) · Drug Development (2) · 8-K (2) · Asthma Treatment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Fiscal Year End | 2025-12-31 | The report covers the financial performance up to this date. |
| Filing Date | 2026-04-16 | The date the Annual Report to Security Holders was officially filed. |
| File Number | 333-291267 | Associated with the registration statement for the filing. |
| Film Number | 26799220 | Internal SEC processing number. |
| Aggregate market value of common equity held by non-affiliates | $467,859,469 | As of June 30, 2025, indicating company size |
| Shares of common stock outstanding | 54,419,986 | As of March 20, 2026 |
| Total estimated biologics sales for asthma | $7.5 billion | In 2023 for US, Europe, and Japan markets, showing market opportunity |
| Projected global annual sales for tezepelumab (severe asthma) | $3.0 billion | By 2032, indicating competitor's market potential |
| Projected global annual sales for tezepelumab (COPD) | $5.0 billion | By 2033, if approved, indicating competitor's market potential |
| Verekitug's potency advantage over tezepelumab | 300-fold | Based on published data, enabling extended dosing |
| Extended dosing interval for verekitug | 24 weeks | Compared to tezepelumab's four-week interval |
| Greater effect on FeNO for verekitug | 50% | Compared to tezepelumab in Phase 1b trials |
| Total participants in Phase 1 clinical trials for verekitug | 120 | Including 32 asthma patients, demonstrating early safety profile |
| Year for planned Phase 3 trial initiation | 2027 | For severe asthma and CRSwNP, indicating next major milestone |
| Net Loss | $100.98M | Increased from $41.56M in 2024 for the nine months, a 143% rise. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Upstream Bio, Inc. (UPB)?
Upstream Bio, Inc. has 20 recent SEC filings from Sep 2024 to Apr 2026, including 6 8-K, 3 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of UPB filings?
Across 20 filings, the sentiment breakdown is: 2 bearish, 17 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Upstream Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Upstream Bio, Inc. (UPB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Upstream Bio, Inc.?
Key financial highlights from Upstream Bio, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for UPB?
The investment thesis for UPB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Upstream Bio, Inc.?
Key executives identified across Upstream Bio, Inc.'s filings include Len Blavatnik, Alejandro Moreno, Langhorne S. Perrow, Nicholas, E. Rand Sutherland and 1 others.
What are the main risk factors for Upstream Bio, Inc. stock?
Of UPB's 16 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Upstream Bio, Inc.?
Forward guidance and predictions for Upstream Bio, Inc. are extracted from SEC filings as they are enriched.